Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 1/5/2022
Cerezyme Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Cerezyme?

Cerezyme (imiglucerase) Injection is a man-made form of the beta-glucocerebrosidase protein used to treat those who have a deficiency of beta-glucocerebrosidase (Gaucher disease) that causes anemia, low platelet count, bone disease, enlargement of the liver, or enlargement of the spleen.

What Are Side Effects of Cerezyme?

Common side effects of Cerezyme include:

  • injection site reactions (discomfort, burning, itching, swelling, or open wound or sore)
  • nausea
  • vomiting
  • abdominal pain
  • diarrhea
  • fatigue
  • headache
  • dizziness, and
  • rash

Dosage for Cerezyme

The recommended dosage of Cerezyme is individualized to each patient and ranges from 2.5 U/kg of body weight 3 times per week to 60 U/kg once every 2 weeks.

What Drugs, Substances, or Supplements Interact with Cerezyme?

Before taking Cerezyme tell your doctor if you have antibodies to or have had allergic reactions to either imiglucerase or alglucerase (Ceredase). There are no known drug interactions to Cerezyme.

Cerezyme During Pregnancy or Breastfeeding

You shouldn't take Cerezyme if you are pregnant unless your doctor determines it to be absolutely necessary. Caution should be taken if you are breastfeeding while taking Cerezyme.

Additional Information

Our Cerezyme (imiglucerase) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


ADHD Symptoms in Children See Slideshow
Cerezyme Consumer Information

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during or shortly after the injection. Tell your caregiver right away if you feel dizzy, itchy, light-headed, sweaty, or have chest pain, cough, trouble breathing, or flushing (warmth, redness, or tingly feeling).

Call your doctor at once if you have:

  • fever, chills, cough with yellow or green mucus;
  • stabbing chest pain, wheezing, feeling short of breath; or
  • worsening or no improvement in your Gaucher disease symptoms.

Common side effects may include:

  • stomach pain, nausea, vomiting, diarrhea;
  • fast heartbeats;
  • headache, dizziness;
  • back pain;
  • fever, chills, tired feeling;
  • mild rash; or
  • itching, burning, swelling, or other discomfort around the IV needle.

Read the entire detailed patient monograph for Cerezyme (Imiglucerase)

Cerezyme Professional Information


Since the approval of Cerezyme® (imiglucerase for injection) in May 1994, Genzyme has maintained a worldwide post-marketing database of spontaneously reported adverse events and adverse events discussed in the medical literature. The percentage of events for each reported adverse reaction term has been calculated using the number of patients from these sources as the denominator for total patient exposure to Cerezyme since 1994. Actual patient exposure is difficult to obtain due to the voluntary nature of the database and the continuous accrual and loss of patients over that span of time. The actual number of patients exposed to Cerezyme since 1994 is likely to be greater than estimated from these voluntary sources and, therefore, the percentages calculated for the frequencies of adverse reactions are most likely greater than the actual incidences.

Experience in patients treated with Cerezyme® has revealed that approximately 13.8% of patients experienced adverse events which were judged to be related to Cerezyme administration and which occurred with an increase in frequency. Some of the adverse events were related to the route of administration. These include discomfort, pruritus, burning, swelling or sterile abscess at the site of venipuncture. Each of these events was found to occur in < 1% of the total patient population.

Symptoms suggestive of hypersensitivity have been noted in approximately 6.6% of patients. Onset of such symptoms has occurred during or shortly after infusions; these symptoms include pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis, and hypotension. Anaphylactoid reaction has also been reported (see WARNINGS). Each of these events was found to occur in < 1.5% of the total patient population. Pre-treatment with antihistamines and/or corticosteroids and reduced rate of infusion have allowed continued use of Cerezyme in most patients.

Additional adverse reactions that have been reported in approximately 6.5% of patients treated with Cerezyme include: nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Each of these events was found to occur in < 1.5% of the total patient population.

Incidence rates cannot be calculated from the spontaneously reported adverse events in the postmarketing database. From this database, the most commonly reported adverse events in children (defined as ages 2 – 12 years) included dyspnea, fever, nausea, flushing, vomiting, and coughing, whereas in adolescents (>12 – 16 years) and in adults (>16 years) the most commonly reported events included headache, pruritis, and rash.

In addition to the adverse reactions that have been observed in patients treated with Cerezyme, transient peripheral edema has been reported for this therapeutic class of drug.

Read the entire FDA prescribing information for Cerezyme (Imiglucerase)

© Cerezyme Patient Information is supplied by Cerner Multum, Inc. and Cerezyme Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors